Han, Tae H <br/><br/>
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.  [electronic resource] 

 -  Journal of clinical pharmacology  Aug 2013 
 - 866-77 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1552-4604 
<br/><br/><label>Standard No.: </label>10.1002/jcph.116  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Brentuximab Vedotin<br/>Cross-Over Studies<br/>Cytochrome P-450 CYP3A--metabolism<br/>Cytochrome P-450 CYP3A Inhibitors<br/>Drug Interactions<br/>Feces--chemistry<br/>Female<br/>Hematologic Neoplasms--metabolism<br/>Humans<br/>Immunoconjugates--administration & dosage<br/>Ketoconazole--administration & dosage<br/>Ki-1 Antigen--immunology<br/>Male<br/>Midazolam--administration & dosage<br/>Middle Aged<br/>Oligopeptides--metabolism<br/>Rifampin--administration & dosage<br/>Young Adult